Literature DB >> 7575773

Cyclosporine treatment reduces early atherosclerosis in the cholesterol-fed rabbit.

A F Drew1, P G Tipping.   

Abstract

While T helper cell infiltration is an early event in the development of atherosclerosis in cholesterol-fed rabbits, their functional contribution to atherogenesis is not clear. To investigate their role, T cell activation was blocked with cyclosporine A (CsA) in New Zealand White (NZW) rabbits fed a 1% cholesterol diet. CsA was administered at a dose of 16 mg/kg body weight, intramuscularly every second day, resulting in circulating whole blood levels of 460 +/- 39 micrograms/l. After 4 weeks on the cholesterol diet, untreated rabbits developed atherosclerotic plaques covering 74.4% +/- 3.5% of their aortic arch, 19.8% +/- 7.8% of their thoracic aorta and 19.8% +/- 6.2% of their abdominal aorta. T cells were observed in plaques of their aortic arches (CD5 positive, 11.1 +/- 7.3 cells/mm2; CD4 positive, 9.9 +/- 4.9 cells/mm2) by immunofluorescence using monoclonal anti-rabbit CD5 and CD4 antibodies. Rabbits treated with CsA developed significantly less extensive plaques after 4 weeks (aortic arch 33.0% +/- 6.2%, P < 0.001; thoracic aorta 6.3% +/- 1.5%, P < 0.05; abdominal aorta 2.7% +/- 0.5%, P < 0.005) than untreated rabbits. No CD4 or CD5 positive cells were observed in their plaques. Treatment with CsA did not affect the weight gain of rabbits or reduce their serum cholesterol levels. Circulating T cell numbers and subsets were unaffected. These studies suggest that inhibition of T cell activation prevents their localisation in plaques and reduces the extent of early lesions, suggesting a role for T cells in the initiation of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7575773     DOI: 10.1016/0021-9150(95)05539-9

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

1.  The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/- mice.

Authors:  A Daugherty; E Puré; D Delfel-Butteiger; S Chen; J Leferovich; S E Roselaar; D J Rader
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

2.  Suppressive effects of anti-inflammatory agents on human endothelial cell activation and induction of heat shock proteins.

Authors:  A Amberger; M Hala; M Saurwein-Teissl; B Metzler; B Grubeck-Loebenstein; Q Xu; G Wick
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

3.  Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice.

Authors:  X Zhou; S Stemme; G K Hansson
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

4.  Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice.

Authors:  E E Emeson; M L Shen; C G Bell; A Qureshi
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

Review 5.  The metabolic effects of cyclosporin and tacrolimus.

Authors:  P Marchetti; R Navalesi
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

6.  Mildly oxidized low-density lipoproteins decrease early production of interleukin 2 and nuclear factor kappaB binding to DNA in activated T-lymphocytes.

Authors:  S Caspar-Bauguil; J Tkaczuk; M J Haure; M Durand; J Alcouffe; M Thomsen; R Salvayre; H Benoist
Journal:  Biochem J       Date:  1999-01-15       Impact factor: 3.857

Review 7.  Endothelial mitochondria--less respiration, more integration.

Authors:  Lukas N Groschner; Markus Waldeck-Weiermair; Roland Malli; Wolfgang F Graier
Journal:  Pflugers Arch       Date:  2012-03-01       Impact factor: 3.657

Review 8.  Immunization for atherosclerosis.

Authors:  Kuang-Yuh Chyu; Jan Nilsson; Prediman K Shah
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.967

9.  Attenuated combined action of cyclosporine a and hyperlipidemia on atherogenesis in rabbits by thymoquinone.

Authors:  Ahmed Ragheb; Ahmed Attia; Fawzy Elbarbry; Kailash Prasad; Ahmed Shoker
Journal:  Evid Based Complement Alternat Med       Date:  2011-05-03       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.